

Supporting Information

Homoleptic complexes of titanium(IV) fused with O[^]N[^]O Schiff Base derivatives: design, BSA-DNA interaction, molecular docking, DFT and cytotoxicity

Shivabasayya V Salimath^a, Kavita B Hiremath^a, Mahabarathi Subramaniyan^a, Arjita Ghosh^b, Evangeline Lawrence^b, Anbalagan Moorthy^b, Murugesh Shivashankar^a and Madhvesh Pathak^{a*}

^aDepartment of Chemistry, School of Advanced Sciences, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India

^bDepartment of Integrative Biology, School of Bioscience and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India

*Email: madhveshpathak@vit.ac.in *ORCID iD: <https://orcid.org/0000-0002-1567-6519>

Figures and tables	Title	Page.No
Fig.S1-S4	NMR, FTIR and ESI-MS data of Ligand [IS]	3-4
Fig.S5-S8	NMR, FTIR and ESI-MS data of Ligand [IN]	5-6
Fig.S9-S12	NMR, FTIR and ESI-MS data of Ligand [IO]	7-8
Fig.S13-S16	NMR, FTIR and ESI-MS data of Ligand [IF]	9-10
Fig.S17-S20	NMR, FTIR and ESI-MS data of Ligand [ICl]	11-12
Fig.S21-S24	NMR, FTIR and ESI-MS data of Ligand [IBr]	13-14
Fig.S25-S29	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-1-IS]	14-17
Fig.S30-S34	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-2-IN]	17-19
Fig.S35-S39	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-3-IO]	20-22
Fig.S40-S45	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-4-IF]	22-25
Fig.S46-S50	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-5-ICl]	25-27
Fig.S51-S55	NMR, FTIR, ESI-MS and HPLC data of Complex [Ti-6-IBr]	28-30
Fig.S56-S57	UV-Vis and Fluorescence spectra of Ti(IV) complexes in DMSO: H ₂ O (1:9)	31
Fig.S58-S59	Stability of complexes in 1:9 DMSO: H ₂ O and GSH medium	32-33
Fig.S60	UV-visible spectra of Ti(IV) complexes for Lipophilicity study of complexes in octanol: water	34
Fig.S61	UV-Visible spectra of DNA Binding studies of Ti(IV) complexes (a)Ti-1-IS, (b) Ti-2-IN, (c) Ti-3-IO, (d) Ti-4-IF, (e) Ti-5-Cl and (f) Ti-6-IBr	35
Fig.S62	Linear plots of DNA UV-binding studies of Ti(IV) complexes	36
Fig.S63	Fluorescence quenching spectra of DNA with increasing concentration of Ti(IV) complexes	37
Fig.S64	Stern-Volmer plots of I ₀ /I vs. Ti(IV) complexes	38
Fig.S64	Scatchard plots of log([I ₀ -I]/I) vs. log [Ti(IV) complexes]	38

Fig.S66	Viscosity studies of Complexes	39
Fig.S67	Cyclic voltammetry DNA binding Studies of Ti(IV) complexes	40
Table S1	Oxidation and reduction peaks obtained from Cyclic Voltammograms of Ti(IV) complexes with CT-DNA(0–50 μM)	41
Fig.S68	Fluorescence quenching spectra of BSA with increasing concentration of Ti(IV) complexes	42
Fig.S69	Stern-Volmer plots of I_0/I vs. Ti(IV) complexes	43
Fig.S70	Scatchard plots of $\log([I_0-I]/I)$ vs. $\log$ [Ti(IV) complexes]	43
Fig.S71	Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=15$ nm,	44
Fig.S72	Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=15$ nm	45
Fig.S73	Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=60$ nm,	45-46
Fig.S74	Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=15$ nm	46
Table S2	Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ru(II) complexes at $\Delta\lambda=15$ nm and 60nm	46
Fig.S75	Site marker fluorescence quenching studies of BSA+Ibuprofen with an increase in the concentration of Ti(IV) complexes	47
Fig.S76	Scatchard plot of $\log([I_0-I]/I)$ vs $\log$ [complex]of site marker fluorescence quenching studies of BSA+Ibuprofen	48
Fig.S77	Site marker fluorescence quenching studies of BSA+Warfarin with an increase in the concentration of Ti(IV) complexes	49
Fig.S78	Scatchard plot of $\log([I_0-I]/I)$ vs $\log$ [complex]of site marker fluorescence quenching studies of BSA+Warfarin	50
Table S3	The comparison of binding constants of the complexes Ti(IV) with BSA before and after the addition of site probe at 298 K	50
Fig.S79-S84	Molecular docking of DNA with Ti(IV) complexes	51-53
Table S4	Docking scores and binding sites of DNA with Ti(IV) complexes	54
Table S5	Docking scores and binding sites of BSA with Ti(IV) complexes	54
Fig.S85-S90	Molecular docking of BSA with Ti(IV) complexes	55-57
Table S6	Bond length ($\text{\AA}$) of Ti(IV) complexes	58
Table S7	Comparison of experimental and theoretical excitation spectral details	58
Fig.S91	DPPH assay of Ti(IV) complexes	59
Fig.S92-S93	MTT assay of Ti(IV) complexes on HeLa and MCF7 cell line	60-61
	References	62




Figure.S1. ^1H NMR spectrum of ligand IS (400 MHz, DMSO- d_6)




Figure.S2. ^{13}C NMR spectrum of ligand IS (400 MHz, DMSO- d_6)




Figure.S3. FTIR spectrum of ligand IS (400 MHz, DMSO- d_6)




Figure.S4. ESI-MS spectrum of ligand IS




Figure.S5. ^1H NMR spectrum of ligand IN (400 MHz, DMSO- d_6)




Figure.S6. ^{13}C NMR spectrum of ligand IN (400 MHz, DMSO- d_6)




Figure.S7. FTIR spectrum of ligand IN (400 MHz, DMSO-d₆)




Figure.S8. ESI-MS spectrum of ligand IN




Figure.S9. ^1H NMR spectrum of ligand IO (400 MHz, DMSO- d_6)




Figure.S10. ^{13}C NMR spectrum of ligand IO (400 MHz, DMSO- d_6)




Figure.S11. FTIR spectrum of ligand IO




Figure.S12. ESI-MS spectrum of ligand IO




Figure.S13. ^1H NMR spectrum of ligand IF(400 MHz, DMSO- d_6)




Figure.S14. ^{13}C NMR spectrum of ligand IF(400 MHz, DMSO- d_6)




Figure.S15. FTIR spectrum of ligand IF (400 MHz, DMSO- d_6)




Figure.S16. ESI-MS spectrum of ligand IF




Figure.S17. ¹H NMR spectrum of ligand ICI (400 MHz, DMSO-d₆)




Figure.S18. ¹³C NMR spectrum of ligand ICI (400 MHz, DMSO-d₆)




Figure.S19. FTIR spectrum of ligand ICI




Figure.S20. ESI-MS spectrum of ligand ICI




Figure.S21. ¹H NMR spectrum of ligand IBr (400 MHz, DMSO-d₆)




Figure.S22. ¹³C NMR spectrum of ligand IBr (400 MHz, DMSO-d₆)




Figure.S23. FTIR spectrum of ligand IBr




Figure.S24. ESI-MS spectrum of ligand IF




Figure.S25. ^1H NMR spectrum of complex Ti-1-IS (400 MHz, DMSO-d_6)




Figure.S26. ^{13}C NMR spectrum of complex Ti-1-IS (400 MHz, DMSO-d_6)




Figure.S27. FTIR spectrum of complex Ti-1-IS (400 MHz, DMSO-d₆)




Figure.S28. ESI-MS spectrum of complex Ti-1-IS





Figure.S29. HPLC spectrum of complex Ti-1-IS






Figure.S31. ^{13}C NMR spectrum of complex Ti-2-IN (400 MHz, DMSO- d_6)




Figure.S32. FTIR spectrum of complex Ti-2-IN




Figure.S33. ESI-MS spectrum of complex Ti-2-IN (400 MHz, DMSO-d₆)




Figure.S34. HPLC spectrum of complex Ti-2-IN




Figure.S35. ¹H NMR spectrum of complex Ti-3-IO (400 MHz, DMSO-d₆)




Figure.S36. ¹³C NMR spectrum of complex Ti-3-IO (400 MHz, DMSO-d₆)




Figure.S37. FTIR spectrum of complex Ti-3-IO




Figure.S38. ESI-MS spectrum of complex Ti-3-IO




Figure.S39. HPLC spectrum of complex Ti-3-IO




Figure.S40. ^1H NMR spectrum of complex Ti-4-IF(400 MHz, DMSO-d_6)




Figure.S41. ^{13}C NMR spectrum of complex Ti-4-IF(400 MHz, DMSO- d_6)




Figure.S42. ^{19}F NMR spectrum of complex Ti-4-IF(400 MHz, DMSO- d_6)




Figure.S43. FTIR spectrum of complex Ti-4-IF




Figure.S44. ESI-MS spectrum of complex Ti-4-IF




Figure.S45. HPLC spectrum of complex Ti-4-IF




Figure.S46. ¹H NMR spectrum of complex Ti-5-ICl (400 MHz, DMSO-d₆)




Figure.S47. ^{13}C NMR spectrum of complex Ti-5-ICl (400 MHz, DMSO- d_6)




Figure.S48. FTIR spectrum of complex Ti-5-ICl




Figure.S49. ESI-MS spectrum of complex Ti-5-ICl




Figure.S50. HPLC spectrum of complex Ti-5-ICl




Figure.S51. ^1H NMR spectrum of complex Ti-6-IBr (400 MHz, DMSO-d_6)




Figure.S52. ^{13}C NMR spectrum of complex Ti-6-IBr (400 MHz, DMSO-d_6)




Figure.S53. FTIR spectrum of complex Ti-6-IBr




Figure.S54. ESI-MS spectrum of complex Ti-6-IBr




Figure.S55. HPLC spectrum of complex Ti-6-IBr




Fig.S56. UV-Vis Spectra of Ti(IV) complexes in DMSO: H₂O (1:9)




Fig.S57. Fluorescence Spectra of Ti(IV) complexes in DMSO: H₂O (1:9)




Fig.S58. UV-Vis stability study of Ti(IV) complexes in 1:9 DMSO: H₂O medium




Fig.S59. UV-Vis stability study of Ti(IV) complexes in GSH medium




Fig. S60. UV-visible spectra of Ti(IV) complexes for Lipophilicity study of complexes in octanol: water




Fig.S61. UV-Visible spectra of DNA Binding studies of Ti(IV) complexes




Fig.S62. Linear plots of DNA UV-binding studies of Ti(IV) complexes




Fig.S63. Fluorescence quenching spectra of DNA with increasing concentration of Ti(IV) complexes




Fig.S64. Stern-Volmer plots of I_0/I vs. Ti(IV) complexes




Fig.S65. Scatchard plot of $\log[(I_0-I)/I]$ vs. $\log [Ti(IV) \text{ complexes}]$




Fig.S66. Viscosity Studies of Ti(IV) complexes




Fig.S67. Cyclic voltammetry DNA binding Studies of Ti(IV) complexes

Table S1: Oxidation and reduction peaks obtained from Cyclic Voltammograms of Ti(IV) complexes with CT-DNA(0–50 μ M)

Complexes	Oxidation peak	Reduction peak
Ti-1-IS	-0.877, 0.533, 1.099	-0.860, -0.117, 1.327
Ti-2-IN	-1.328, -0.924, -0.233	-0.920, -0.335
Ti-3-IO	-0.892, -0.264	-0.900, -0.355, -0.665, 1.161
Ti-4-IF	-0.892, -0.417, 1.16	-0.892, -0.148, 0.859
Ti-5-ICI	-0.932, 0.425	-0.916, -0.218, 0.750
Ti-6-IBr	-0.908, 0.440, 1.239	-1.249, -0.908, -0.055




Fig.S68. Fluorescence quenching spectra of BSA with increasing concentration of Ti(IV) complexes




Fig.S69. Stern-Volmer plots of I_0/I vs. complex




Fig.S70. Scatchard plot of $\log([I_0 - I]/I)$ vs. $\log [\text{complex}]$




Fig.S71. Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=15$ nm





Fig.S72. Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=15$ nm






Fig.S73. Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=60$ nm




Fig.S74. Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ti(IV) complexes at $\Delta\lambda=60$ nm

Table S2; Stern-Volmer plots of I_0/I vs. complex of Synchronous spectra of BSA with increasing concentration of Ru(II) complexes at $\Delta\lambda=15$ nm and 60nm

Complexes	Ka	Ka
	$\Delta\lambda=15\text{nm}$	$\Delta\lambda=60\text{ nm}$
Ti-1-IS	0.1444	0.0334
Ti-2-IN	0.0150	0.0445
Ti-3-IO	0.0803	0.1882
Ti-4-IF	0.5071	0.6377
Ti-5-ICl	0.2911	0.1084
Ti-6-IBr	0.1376	0.3096




Fig.S75. Site marker fluorescence quenching studies of BSA+Ibuprofen with an increase in the concentration of Ti(IV) complexes




Fig.S76. Scatchard plot of $\log([I_0-I]/I)$ vs $\log [\text{complex}]$ of site marker fluorescence quenching studies of BSA+Ibuprofen




Fig.S77. Site marker fluorescence quenching studies of BSA+Warfarin with an increase in the concentration of Ti(IV) complexes




Fig.S78. Scatchard plot of $\log([I_0-I]/I)$ vs $\log [\text{complex}]$ of site marker fluorescence quenching studies of BSA+Warfarin

Table S3; The comparison of binding constants of the complexes Ti(IV) with BSA before and after the addition of site probe at 298 K. K_b binding constant ^a

COMPLEXES	BSA $K_b^a (\times 10^4 \text{ M}^{-1})$	BSA+Ibuprofen $K_b^a (\times 10^4 \text{ M}^{-1})$	BSA + Warfarin $K_b^a (\times 10^4 \text{ M}^{-1})$
Ti-1-IS	0.040	0.034	0.048
Ti-2-IN	0.047	0.015	0.069
Ti-3-IO	0.036	0.050	0.058
Ti-4-IF	0.011	0.037	0.040
Ti-5-ICl	0.065	0.035	0.016
Ti-6-IBr	0.014	0.054	0.039




Fig.S79. Molecular docking of DNA with Ti-1-IS; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S80. Molecular docking of DNA with Ti-2-IN ; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S81. Molecular docking of DNA with Ti-3-IO ; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S82. Molecular docking of DNA with Ti-4-IF ; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S83. Molecular docking of DNA with Ti-5-ICl ; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S84. Molecular docking of DNA with Ti-6-IBr ; purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms

Table S4; Docking scores and binding sites of DNA with Ti(IV) complexes

Complexes	Nucleotides	Docking scores in kcal/mol
Ti-1-IS	DC3, DG4, DT19, DC21, DG22	-9.3
Ti-2-IN	DG2, DG4, DC3, DC21, DT20	-10.3
Ti-3-IO	DA6, DG22	-8.4
Ti-4-IF	DC3, DG4, DC21, DG22	-9.7
Ti-5-ICl	DC21, DG22, DC3	-9.7
Ti-6-IBr	DG4,DA5,DA6,DA16, T19	-9.5

Table S5; Docking scores and binding sites of BSA with Ti(IV) complexes

Complexes	Amino acid residues	Docking scores in kcal/mol
Ti-1-IS	GLU182, ARG185, PRO117, LYS116, LEU115, LYS114, PRO516	-10.8
Ti-2-IN	SER109, LYS114, ARG427, GLU424, THR421, PRO420	-11.5
Ti-3-IO	PRO420, VAL423, ILE522, GLU424, SER109, PRO110, ARG144	-9.2
Ti-4-IF	GLU125, THR121, LEU122, LYS136, GLU140, LEU115, LYS116, ASP118	-9.8
Ti-5-ICl	ASP118, THR121, LEU122, GLU125, LYS132, LYS136, GLU140, PRO113, LEU115, LYS116, LEU115, LYS116	-9.9
Ti-6-IBr	THR121, GLU125, LYS132, LYS136, GLU140, LYS116, ASP118, LEU122	-9.7




Fig.S85. Molecular docking of BSA with Ti-1-IS purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S86. Molecular docking of BSA with Ti-2-IN purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S87. Molecular docking of BSA with Ti-3-IO purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S88. Molecular docking of BSA with Ti-4-IF purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S89. Molecular docking of BSA with Ti-5-ICl purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms




Fig.S90. Molecular docking of BSA with Ti-6-IBr purple color indicates carbon atoms, blue color indicates nitrogen, grey color indicates titanium(IV) ion, red color indicates oxygen atoms

Table S6; Bond length (Å) of Ti(IV) complexes

S. NO	Code	O-Ti	N-Ti	O-Ti
1	Ti-1-IS	1.997	2.886	2.032
2	Ti-2-IN	1.997	2.887	2.031
3	Ti-3-IO	2.031	2.882	2.032
4	Ti-4-IF	1.998	2.885	2.030
5	Ti-5-ICl	2.001	2.886	2.031
6	Ti-6-IBr	2.000	2.885	2.029

Table S7; Comparison of experimental and theoretical excitation spectral details

Code	Experimental	Theoretical Prediction			
	Abs (nm)	Abs. max (nm)	Oscillator strength (f)	Transition	Orbital Contribution
Ti-1-IS	339	389	0.325	S ₀ →S ₉	H→L+4 82%, H-3→L 3%,
Ti-2-IN	341	378	0.233	S ₀ →S ₁₀	H→L+4 46%, H-3→L 19%,
Ti-3-IO	340	412	0.298	S ₀ →S ₁₂	H→L+3 68%, H-3→L 12%,
Ti-4-IF	343	406	0.282	S ₀ →S ₁₀	H→L+5 48%, H-4→L 26%,
Ti-5-ICl	345	443	0.316	S ₀ →S ₁₁	H→L+3 55%, H→L+4 21%,
Ti-6-IBr	343	625	0.238	S ₀ →S ₁₀	H→L+5 78%, H-4→L 6%,

*H – HOMO, L - LUMO

H→L+4 83%, H-4→L+2 4%




Fig.S91. DPPH assay of Ti(IV) complexes




Fig.S92. MTT assay of Ti(IV) complexes on HeLa cell line




Fig.S93. MTT assay of Ti(IV) complexes on MCF7 cell line

References:

1. Subramaniyan, Mahabarathi, et al. "New bioactive titanium (IV) derivatives with their DFT, molecular docking, DNA/BSA interaction, antioxidant and in-vitro investigations." *Inorganica Chimica Acta* 571 (2024): 122191.
2. Thanigachalam, Sathish, et al. "Bioactive O[^]N[^]O[^] Schiff base appended homoleptic titanium (iv) complexes: DFT, BSA/CT-DNA interactions, molecular docking and antitumor activity against HeLa and A549 cell lines." *RSC advances* 14.19 (2024): 13062-13082.
3. Dorairaj, Dorothy Priyanka, et al. "Ru (II)-p-Cymene complexes of furoylthiourea ligands for anticancer applications against breast cancer cells." *Inorganic Chemistry* 62.30 (2023): 11761-11774.
4. Haribabu, Jebiti, et al. "Michael addition-driven synthesis of cytotoxic palladium (ii) complexes from chromone thiosemicarbazones: investigation of anticancer activity through in vitro and in vivo studies." *New Journal of Chemistry* 47.33 (2023): 15748-15759.
5. Arunachalam, Abirami, et al. "Synthesis and Structure of Naphthoyl Thiourea-Based Binuclear Ruthenium (II) Arene Complexes: Studies on Anticancer Activity and Apoptotic Mechanism." *ChemBioChem*: e202500057.
6. Monika, Sankar, et al. "Binuclear Ruthenium (II) Complexes Featuring Arylthiourea Ligands: Synthesis, Crystal Structure and Anticancer Assessment." *Applied Organometallic Chemistry* 39.5 (2025): e70146.
7. Kar, Binoy, et al. "2-Aryl-1 H-imidazo [4, 5-f][1, 10] phenanthroline-Based Binuclear Ru (II)/Ir (III)/Re (I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents#." *Journal of Medicinal Chemistry* 67.13 (2024): 10928-10945.
8. Das, Utpal, et al. "Exploring the phototoxicity of GSH-resistant 2-(5, 6-dichloro-1 H-benzo [d] imidazol-2-yl) quinoline-based Ir (III)-PTA complexes in MDA-MB-231 cancer cells." *Dalton Transactions* 53.14 (2024): 6459-6471.